Seletalisib Shows Trend Toward Easing Primary Sjögren’s in Phase 2 Trial
Using the PI3K-delta inhibitor seletalisib as an add-on to standard treatment showed a trend toward easing disease activity and dryness, and significantly lowered patient-reported fatigue in people with primary Sjögren’s syndrome (pSS), according to data from a Phase 2 trial. Findings from this proof-of-concept study (NCT02610543) —…